Form D · Biotechnology

BioLattice Ophthalmics, Inc,

Philadelphia, PA · CIK 0002125596

Offering snapshot reported Oct 28, 2026 · SEC filing

Reported sold
$1.83M
Offering amount: $3.31M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 6, 2026
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$913K$1.83MMar 30, 2026: $575,000.00Mar 30, 2026Oct 28, 2026: $1,825,000.00Oct 28, 2026

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$575,000 → $1,825,000
  • Reported investors2 → 7

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 28, 2026Amendment$1,825,000$1,250,000vs Mar 30, 20267SEC filing
Mar 30, 2026Initial$575,000No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-578200

Source: Form D, filed Oct 28, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Linda Alunkal Director, Executive
Gregory Jackson Director
Amelia Zellander Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2929 Arch Street
Philadelphia, PA, 19104